Sirolimus-Eluting Balloon in Femoropopliteal Disease

Drug-eluting balloons (DEB) with paclitaxel have shown efficacy and safety in the treatment of femoropopliteal disease. Sirolimus-eluting balloons (DEB S) are currently being introduced.

This new drug acts during the cellular resting phase (G0) and is considered potentially more effective than paclitaxel, which is a cytostatic drug. However, there is no conclusive evidence in this regard yet.

The SELUTION SFA study included 134 patients with femoropopliteal intermittent claudication who received percutaneous transluminal angioplasty (PTA) with a DEB S.

The primary endpoint (PEP) was primary patency, defined as restenosis (peak systolic velocity ≥2.5) and clinically driven target lesion revascularization.

The mean patient age was 74 years, and most subjects were men. Overall, 60% of patients had diabetes, 90% had hypertension, 7% had renal insufficiency, and 22% had suffered a stroke. 

Additionally, 97% of the patients were at Rutherford stage 2 or 3. Mean lesion length was 124 mm and the vessel diameter was 5 mm, with 23% total occlusions and 27% moderate to severe calcification.

Read also: Pacientes con antecedente de cirugía de revascularización miocárdica y un nuevo evento de SCA no ST ¿Estrategia invasiva rutinaria?

Technical success was achieved in all patients, with a procedural success rate of 96%. The residual lesion rate was 20% and 2% of patients required bailout stenting.

At 12 months, the PEP was 87.9%, and the rate for clinically driven target lesion revascularization reached 97%. The non-related mortality rate was 6.5%; there were no amputations, and researchers observed a sustained improvement in functional class and an increase in the ankle-brachial index.

Conclusion

The SELUTION SFA JAPAN study showed that the new SELUTION sirolimus-eluting balloon is safe and effective for the treatment of femoropopliteal disease in symptomatic patients.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions The SELUTION SFA Japan Trial.

Reference: Osamu Iid, et al. J Am Coll Cardiol Intv 2024 Article in Press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

Safety of Prophylactic Spinal Fluid Drainage in Open and Endovascular Repair of Thoracic and Thoracoabdominal Aortic Aneurysms

Spinal cord injury remains one of the most devastating complications of thoracic and thoracoabdominal aneurysm repair, mainly associated to a compromised the Adamkiewicz artery...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....